Women's Health Issues
Volume 20, Issue 5 , Pages 335-342 , September 2010

Multi-Dimensional Risk Factor Patterns Associated with Non-Use of Highly Active Antiretroviral Therapy among Human Immunodeficiency Virus-Infected Women

  • Alison Snow Jones, PhD

      Affiliations

    • Department of Health Management & Policy, Drexel University School of Public Health, Philadelphia, Pennsylvania
    • Corresponding Author InformationCorrespondence to: Dr. Alison Snow Jones, Drexel University School of Public Health, Department of Health Management & Policy, 1505 Race Street, MS 1035, Philadelphia, PA 19102. Phone: 215-762-2568; fax: 215-762-8846.
    • ,
  • Marsha Lillie-Blanton, DrPH

      Affiliations

    • Department of Health Policy, George Washington University School of Public Health and Health Services, Washington, DC
    • ,
  • Valerie E. Stone, MD, MPH

      Affiliations

    • Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Edward H. Ip, PhD

      Affiliations

    • Department of Biostatistical Sciences; Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Qiang Zhang, MA

      Affiliations

    • Department of Biostatistical Sciences; Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Tracey E. Wilson, PhD

      Affiliations

    • Department of Community Health Sciences, SUNY Downstate Medical Center, Brooklyn, New York
    • ,
  • Mardge H. Cohen, MD

      Affiliations

    • Departments of Medicine, Stroger Hospital and Rush University, Chicago, Illinois
    • ,
  • Elizabeth T. Golub, PhD, MPH

      Affiliations

    • Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
    • ,
  • Nancy A. Hessol, MSPH

      Affiliations

    • Departments of Clinical Pharmacy and Medicine, University of California, San Francisco

Received 7 August 2009 ,Revised 5 March 2010 ,Accepted 9 March 2010.

References 

  1. Andersen R, Bozzette S, Shapiro M, St CP, Morton S, Crystal S, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Services Research. 2000;35:389–416
  2. Bacon MC, von WV, Alden C, Sharp G, Robison E, Hessol N, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clinical and Diagnostic Laboratory Immunology. 2005;12:1013–1019
  3. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV study. WIHS Collaborative Study Group Epidemiology. 1998;9:117–125
  4. Clark RA, Kissinger P, Bedimo AL, Dunn P, Albertin H. Determination of factors associated with condom use among women infected with human immunodeficiency virus. International Journal of STD and AIDS. 1997;8:229–233
  5. Cohen MH, Cook JA, Grey D, Young M, Hanau LH, Tien P, et al. Medically eligible women who do not use HAART: The importance of abuse, drug use, and race. American Journal of Public Health. 2004;94:1147–1151
  6. Colman I, Ploubidis GB, Wadsworth ME, Jones PB, Croudace TJ. A longitudinal typology of symptoms of depression and anxiety over the life course. Biological Psychiatry. 2007;62:1265–1271
  7. Cook JA, Cohen MH, Burke J, Grey D, Anastos K, Kirstein L, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. Journal of Acquired Immune Deficiency Syndromes. 2002;30:401–409
  8. Cook JA, Cohen MH, Grey D, Kirstein L, Burke J, Anastos K, et al. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. American Journal of Public Health. 2002;92:82–87
  9. Cook JA, Grey DD, Burke-Miller JK, Cohen MH, Vlahov D, Kapadia F, et al. Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug and Alcohol Dependence. 2007;89:74–81
  10. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. Journal of Acquired Immune Deficiency Syndromes. 2000;25:115–123
  11. Dufour MC. What is moderate drinking? Defining “drinks” and drinking levels. Alcohol Research & Health. 1999;23:5–14
  12. Duncan AE, Bucholz KK, Neuman RJ, Agrawal A, Madden PA, Heath AC. Clustering of eating disorder symptoms in a general population female twin sample: A latent class analysis. Psychological Medicine. 2007;37:1097–1107
  13. Huang GH, Bandeen-Roche K. Building an identifiable latent class model with covariate effects on underlying and measured variables. Psychometrika. 2004;69:5–32
  14. Ip, E. H., Snow Jones, A., Heckert, D. A., Zhang, Q., & Gondolf, E. D. (Forthcoming). Latent Markov model for analyzing temporal configuration for violence profiles and trajectories in a sample of batterers. Sociological Methods and Research.
  15. Kaiser Commission on Medicaid and the Uninsured. The uninsured: A primer (see data notes, pg. 32). Menlo Park, CA: Henry J. Kaiser Family Foundation; 2008;
  16. Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Longitudinal study of men and women. Clinical Infectious Diseases. 2007;45:1377–1385
  17. Lee BR, Thompson R. Examining externalizing behavior trajectories of youth in group homes: Is there evidence for peer contagion?. Journal of Abnormal Child Psychology. 2009;37:31–44
  18. Levine RS, Briggs NC, Kilbourne BS, King WD, Fry-Johnson Y, Baltrus PT, et al. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. American Journal of Public Health. 2007;97:1884–1892
  19. Liang KY, Zeger SL. Longitudinal data-analysis using generalized linear-models. Biometrika. 1986;73:13–22
  20. Lillie-Blanton M, Stone VE, Snow Jones A, Levi J, Golub ET, Cohen MH, et al. Association of race, substance abuse, and health insurance in use of highly active antiretroviral therapy among HIV-infected women, 2005. American Journal of Public Health. 2009;Nov 17 [Epub ahead of print]
  21. MacDonald IL, Zucchini W. Hidden Markov and other models for discrete-valued time series. London: Chapman & Hall; 1997;
  22. Martino SC, Ellickson PL, Klein DJ, McCaffrey D, Edelen MO. Multiple trajectories of physical aggression among adolescent boys and girls. Aggressive Behavior. 2008;34:61–75
  23. Novotna L, Wilson TE, Minkoff HL, McNutt LA, DeHovitz JA, Ehrlich I, et al. Predictors and risk-taking consequences of drug use among HIV-infected women. Journal of Acquired Immune Deficiency Syndromes. 1999;20:502–507
  24. Palacio H, Li XH, Wilson TE, Sacks H, Cohen MH, Richardson J, et al. Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety. AIDS. 2004;18:621–630
  25. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998;338:853–860
  26. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction. 2004;99:361–368
  27. Radloff IS. The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement. 1977;1:385–401
  28. Rijmen F, Ip E, Rapp S, Shaw E. Qualitative longitudinal analysis of symptoms in patients with primary or metastatic brain tumors. Journal of Royal Statistical Society A. 2008;171:739–753
  29. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcoholism-Clinical and Experimental Research. 2004;28:572–577
  30. SAS Institute. PROC GENMOD, SAS vs. 9.1.3. Cary, NC: [Computer software]; 2005;
  31. Schwarz G. Estimating dimension of a model. Annals of Statistics. 1978;6:461–464
  32. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al. Variations in the care of HIV-infected adults in the United States—Results from the HIV cost and services utilization study. JAMA: Journal of the American Medical Association. 1999;281:2305–2315
  33. Skurnick JH, Abrams J, Kennedy CA, Valentine SN, Cordell JR. Maintenance of safe sex behavior by HIV-serodiscordant heterosexual couples. AIDS Education and Prevention. 1998;10:493–505
  34. Smith DJ, Ecob R. An investigation into causal links between victimization and offending in adolescents. The British Journal of Sociology. 2007;58:633–659
  35. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medicine. 2003;114:573–580
  36. Viterbi AJ. Error bounds for convolutional codes and an asymptotically optimal decoding algorithm. IEEE Transaction, Information Theory. 1967;13:260–269
  37. Wilson TE. Sexual and reproductive behavior of women with HIV infection. Clinical Obstetrics and Gynecology. 2001;44:289–299
  38. Wilson TE, Barron Y, Cohen M, Richardson J, Greenblatt R, Sacks HS, et al. Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clinical Infectious Diseases. 2002;34:529–534

 The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Institute on Drug Abuse, the National Cancer Institute, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). The National Institute on Drug Abuse (R21 DA022971-01) provided primary funding for this study.

PII: S1049-3867(10)00036-8

doi: 10.1016/j.whi.2010.03.005

Women's Health Issues
Volume 20, Issue 5 , Pages 335-342 , September 2010

Article Tools

* Image Usage & Resolution